GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) » Definitions » EV-to-EBIT

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) EV-to-EBIT : -0.17 (As of May. 17, 2024)


View and export this data going back to 2016. Start your Free Trial

What is ExpreS2ion Biotech Holding AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ExpreS2ion Biotech Holding AB's Enterprise Value is kr17.21 Mil. ExpreS2ion Biotech Holding AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-99.99 Mil. Therefore, ExpreS2ion Biotech Holding AB's EV-to-EBIT for today is -0.17.

The historical rank and industry rank for ExpreS2ion Biotech Holding AB's EV-to-EBIT or its related term are showing as below:

OSTO:EXPRS2' s EV-to-EBIT Range Over the Past 10 Years
Min: -39.4   Med: -4.5   Max: 0.21
Current: -0.17

During the past 11 years, the highest EV-to-EBIT of ExpreS2ion Biotech Holding AB was 0.21. The lowest was -39.40. And the median was -4.50.

OSTO:EXPRS2's EV-to-EBIT is ranked worse than
100% of 431 companies
in the Biotechnology industry
Industry Median: 10 vs OSTO:EXPRS2: -0.17

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ExpreS2ion Biotech Holding AB's Enterprise Value for the quarter that ended in Dec. 2023 was kr52.58 Mil. ExpreS2ion Biotech Holding AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-99.99 Mil. ExpreS2ion Biotech Holding AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -190.16%.


ExpreS2ion Biotech Holding AB EV-to-EBIT Historical Data

The historical data trend for ExpreS2ion Biotech Holding AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ExpreS2ion Biotech Holding AB EV-to-EBIT Chart

ExpreS2ion Biotech Holding AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.67 -6.24 -21.22 -4.08 -0.53

ExpreS2ion Biotech Holding AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.08 -1.02 -0.69 0.02 -0.53

Competitive Comparison of ExpreS2ion Biotech Holding AB's EV-to-EBIT

For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ExpreS2ion Biotech Holding AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ExpreS2ion Biotech Holding AB's EV-to-EBIT falls into.



ExpreS2ion Biotech Holding AB EV-to-EBIT Calculation

ExpreS2ion Biotech Holding AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=17.212/-99.985
=-0.17

ExpreS2ion Biotech Holding AB's current Enterprise Value is kr17.21 Mil.
ExpreS2ion Biotech Holding AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-99.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ExpreS2ion Biotech Holding AB  (OSTO:EXPRS2) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ExpreS2ion Biotech Holding AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-99.985/52.57855
=-190.16 %

ExpreS2ion Biotech Holding AB's Enterprise Value for the quarter that ended in Dec. 2023 was kr52.58 Mil.
ExpreS2ion Biotech Holding AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-99.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ExpreS2ion Biotech Holding AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ExpreS2ion Biotech Holding AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Business Description

Traded in Other Exchanges
Address
c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, S-252 25
ExpreS2ion Biotech Holding AB has developed a technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. The company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with research institutions and companies.

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Headlines

No Headlines